Comments
Drug-maker Wockhardt Ltd formalised a deal with the US-based Sheffield Bio-Science to supply recombinant insulin in cell culture markets, across the world.
Sheffield Bio-Science, a Kerry Group Business company, will have exclusive sales and distribution rights to supply recombinant insulin in designated cell-culture markets estimated at $ 50 million, a Wockhardt note said.
As a part of the alliance, over a period of time, Wockhardt would develop and supply Animal Component Free (ACF) recombinant insulin for distribution in cell-culture markets, the note added.
On Monday, the company's shares ended up 0.36 per cent at Rs 364 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.